SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its recent listing on Bifinance, which the community believes will increase liquidity and exposure. The community is also excited about upcoming utilities, including staking and sweepstakes. Many community members are sharing a Forbes article discussing Brokecoin.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending amid community excitement around potential connections to Elon Musk and Grok, fueling speculation within the AI meme coin sector. Community members highlight a substantial weekly surge and notable whale activity, contributing to the upward momentum. The 'Byte Army' is rallying, with holders expressing strong confidence in the project's potential.

Southern Copper Corp. engages in the development, production, and exploration of copper, molybdenum, zinc, and silver. It operates through the following segments: Peruvian Operations, Mexican Open-Pit Operations, and Mexican Underground Mining Operations. The Peruvian Operations segment focuses on the Toquepala and Cuajone mine complexes and the smelting and refining plants, industrial railroad, and port facilities that service both mines. The Mexican Open-Pit Operations segment comprises the La Caridad and Buenavista mine complexes, the smelting, and refining plants and support facilities, which service both mines. The Mexican Underground Mining Operations segment is involved in the operation of five underground mines, a coal mine, and several industrial processing facilities. The company was founded on December 12, 1952 and is headquartered in Phoenix, AZ.

Southern Copper Corporation

Southern Copper is trending as investors discuss potential opportunities driven by a possible copper supply deficit due to mine shutdowns and rallying copper prices, especially relative to peers like Freeport-McMoRan. Community members are actively analyzing call options and potential ROI, while also weighing factors like geopolitical risks in Peru and future demand related to energy transition and electrification. Some analysts highlight valuation concerns and potential pullbacks, while others emphasize the long-term bullish outlook for copper.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol is trending as the community discusses potential whale activity and a possible Binance listing, with some drawing comparisons to other AI-crypto crossover plays. Despite mixed sentiment and some concerns about supply, optimism persists for a potential pump, particularly if it gets listed on Binance. Many are closely watching for a breakout and anticipating a significant move based on technical indicators.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injective is trending due to Pineapple Financial's $100 million investment to purchase and stake INJ, which could remove a significant portion of the circulating supply and potentially drive price action. The community is also closely watching the Injective-based meme coin, $NONJA.X, with many believing it will outperform INJ, especially if Injective gains further momentum, while also noting the upcoming potential ETF.

Dogelon Mars

Dogelon Mars is trending, with community members actively discussing potential listings and large token transfers sparking speculation. Some investors are focused on technical analysis, identifying flag patterns and potential price targets, while others express frustration with the token's performance and unfulfilled promises. Despite mixed sentiment, some remain hopeful, drawing comparisons to other meme coins and anticipating a potential rally.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as community members discuss its potential for growth, drawing comparisons to other meme coins like Doge and Shiba Inu. Some users are highlighting Floki's utility and ecosystem, while others focus on technical analysis and potential breakout patterns. The community also mentions potential catalysts like the launch of Valhalla and overall altcoin season.

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Mckesson Corporation

Mckesson is trending due to positive ratings updates from analysts and community discussion around potential ROI on call options. The healthcare distributor recently presented at investor day, and traders are actively discussing potential breakout opportunities. Community members are pointing to the company's consistent revenue and defensive qualities as reasons for optimism.

HCA Healthcare, Inc. is a health care services company engaged in operating hospitals, freestanding surgery centers and emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, physician practices, home health, hospice, outpatient physical therapy home and community-based services providers, and various other facilities. The firm operates general and acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services, and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was founded by Dr. Thomas F. Frist, Jr in 1968 and is headquartered in Nashville, TN.

HCA Healthcare Inc

HCA Healthcare is trending as analysts adjust their ratings and price targets following recent earnings and forward guidance, with community members weighing the company's premium valuation against strong cash flow and demographic-driven demand. Despite positive EPS and revenue beats in Q2, discussions highlight concerns about labor costs, debt, and potential sector headwinds, while others point to institutional accumulation and relative strength.

Apollo Global Management, Inc. provides asset management services. It offers its clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business strategies: yield, hybrid, and equity. It operates through following segments: Asset Management, Retirement Services and Principal Investing. The Asset Management segment focuses on credit and equity investing strategies. The Retirement Services and Principal Investing segment consists of realized performance fee income, realized investment income from balance sheet investments, and certain allocable expenses related to corporate functions supporting the entire company. The company was founded by Marc Rowan in 1990 and is headquartered in New York, NY.

Apollo Global Management Inc - Ordinary Shares - Class A (New)

Apollo Global Management Inc

Apollo Global Management is trending as the company expands its reach into new markets, including launching three evergreen ELTIFs to broaden private market access and a potential partnership with Schroders. Community members are discussing the firm's inorganic growth strategy, bold move into evergreen ELTIFs, and Deutsche Bank's upgraded rating to Buy. Option flow indicates bullish sentiment as well.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE? 

ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.

Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?

Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.

AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?

AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.

Johnson & Johnson (JNJ) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Should You Invest in Johnson & Johnson (JNJ) Based on Bullish Wall Street Views?

Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures

SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.

U.S. President Donald Trump’s caution against Tylenol has reignited scrutiny of Kenvue, just as the U.S. FDA moves to add pregnancy-related autism warnings to acetaminophen labels and has alerted physicians nationwide.&nbsp;Although the agency acknowledged that no causal link has been established, plaintiffs’ lawyers say the new language could revive litigation dismissed by a federal court last December, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-23/tylenol-maker-kenvue-faces-mounting-crisis-after-trump-s-rebuke">report</a>.&nbsp;The heightened risk comes as Kenvue, under interim CEO Kirk Perry, faces weak sales, activist investor demands, and a portfolio review. Tylenol, its largest brand, contributes a mid- to high-single-digit share of revenue.&nbsp;Despite the legal overhang, Kenvue’s stock shrugged off concerns, rising 1.6% in regular trade and another 0.8% after hours on Tuesday. Investors took comfort in the fact that the FDA stopped short of a ban and that no new scientific evidence was presented.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-kenvue-stock-rising-today/chDhDbOR350">Citigroup said it sees limited legal risk</a> and expects shares to trade higher, while Evercore ISI cut its price target to $18. Barclays argued that the recent selloff looks overdone, even under highly unlikely worst-case scenarios.The move may also mark Kenvue’s biggest reputational test since the 1980s Tylenol cyanide poisonings, with concerns&nbsp;that it could create confusion for patients who need to treat fevers during pregnancy.Plaintiffs’ lawyer Mark Lanier said the FDA move breathes new life into lawsuits, while legal experts noted courts rarely overturn the agency’s risk assessments. Kenvue stated that the claims lack both legal and scientific merit. Johns Hopkins professor Stacey Lee said even without proving causality, the label could be powerful evidence before juries.The company has been unsettled since its 2023 spin-off from Johnson &amp; Johnson. Former CEO Thibaut Mongon struggled to stabilize operations, prompting pressure from activist hedge funds Starboard Value, TOMS Capital, and Third Point. Kenvue responded by naming Perry interim CEO, adding Starboard’s Jeffrey Smith to its board, and&nbsp;considering the sale&nbsp;of smaller skincare brands, such as Neutrogena.The business faces a&nbsp;challenging consumer backdrop of inflation, high interest rates, and weaker demand, which has led to two consecutive quarters of declining organic sales and a reduction to its full-year forecast.&nbsp;On Stocktwits, retail sentiment for Kenvue was ‘bullish’ amid a 270% surge in 24-hour message volume.One user pointed out that no direct causal link between pregnancy and autism has been established and described the stock as a “huge buying opportunity,” adding that they bought shares after hours and expect it to soon reach $21.<stembedurl>https://stocktwits.com/Mukulu2025/message/629750922</stembedurl>Another bullish user called Kenvue a “great investment opportunity.”<stembedurl>https://stocktwits.com/Little_thebodyguard/message/629750599</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tylenol, which contains acetaminophen, is offered for sale at a drug store on April 14, 2015 in Chicago, Illinois. (Photo by Scott Olson/Getty Images)

Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’

Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry.

Equity

Shares of Johnson &amp; Johnson held up better than its consumer spinoff, Kenvue, on Monday after U.S. President Donald Trump linked autism to Tylenol and childhood vaccines, claims that decades of scientific research have not supported.&nbsp;J&amp;J shares slipped 1.1% to $174.21 in regular trade before gaining 0.5% after hours. Meanwhile, Kenvue fell 7.5% to a record low at $16.97 before rebounding 4.4% in late trading.&nbsp;Guggenheim upgraded J&amp;J to ‘Buy’ from ‘Neutral’ with a raised price target of $206 from $167, which implies an upside of 18% from J&amp;J’s closing price on Monday.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kenvue-stock-hits-record-low-trump-urges-pregnant-women-fight-like-hell-against-tyleno/chDhg0tR3PR">Trump’s sharp warnings against acetaminophen</a>, the active ingredient in Tylenol, directly pressured Kenvue, while J&amp;J moved lower more modestly, supported by its diversified portfolio and pipeline updates.Johnson &amp; Johnson has also remained a defensive play for income investors. The company went ex-dividend on Aug. 26, with its most recent quarterly payout made on Sept. 9, underscoring its steady record of shareholder returns even as sector peers face volatility.Earlier this month, Josh Brown, CEO of Ritholtz Wealth Management, told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/09/16/josh-browns-best-stocks-in-the-market-johnson-johnson.html">CNBC</a> that J&amp;J’s transformation into a pure-play healthcare company after spinning off Kenvue, coupled with a pipeline focused on oncology, immunology, neuroscience, and medtech, is helping steady sentiment. He noted the stock has been “building a base” for years and could be on the verge of a breakout if it clears long-term resistance.The company also drew attention in the U.S. Psychiatric and Mental Health Congress, where it released Phase 3 data for its investigational depression treatment seltorexant on Monday. The trial showed the drug has efficacy similar to that of quetiapine XR, a frequently used adjunctive therapy, but was well-tolerated with&nbsp;fewer adverse events like drowsiness and weight gain.&nbsp;While it did not hit its primary target, seltorexant was still better tolerated as measured by a higher completion rate at week 26, supporting its use in patients with major depressive disorder who are still suffering from insomnia symptoms.On Friday, J&amp;J also said the FDA approved a subcutaneous induction regimen of Tremfya for adults with ulcerative colitis, making it the first IL-23 inhibitor to offer both SC and IV induction options for UC and Crohn’s disease, which&nbsp;affects about 3 million Americans.&nbsp;On Stocktwits, retail sentiment&nbsp;for JNJ,&nbsp;however, was ‘extremely bearish’ amid&nbsp;a 1,720% spike in 24-hour message volume. One user said J&amp;J could still face billions in liability from Tylenol autism suits despite Kenvue assuming primary responsibility after the 2023 spin-off, especially when combined with ongoing talc cases.&nbsp;<stembedurl>https://stocktwits.com/StormChaser/message/629585491</stembedurl>Another&nbsp;user jokingly remarked that with more than 66,000 talc plaintiffs and fresh Tylenol claims, J&amp;J might soon “own the largest law firm in the world.”<stembedurl>https://stocktwits.com/Suite510/message/629583920</stembedurl><a href="https://stocktwits.com/symbol/JNJ">Johnson &amp; Johnson’s stock</a> has risen 23.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Johnson and Johnson American multinational of medical, pharmaceutical and perfumery products headquartes on 28 January 2025 in Madrid, Spain.

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check?

Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks.

U.S. President Donald Trump on Monday linked autism to both childhood vaccines and the use of Tylenol by pregnant women and children, claims that decades of scientific research have not supported.&nbsp;Meanwhile, Kenvue, the maker of Tylenol, rejected the claims. “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/trump-expected-link-autism-with-tylenol-experts-say-more-research-needed-2025-09-22/">report</a>, citing a company statement.&nbsp;Kenvue, which was spun off from Johnson &amp; Johnson in 2023, saw its shares fall 7.5% during Monday’s session to a record low before recovering 4.4% in extended trading.In a White House news conference, Trump repeatedly advised women and parents not to use the painkiller, saying, “Don’t take Tylenol. Fight like hell not to take it,” while acknowledging he was not a doctor.Standing alongside Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, Trump also called for a reexamination of vaccine schedules, urging separate measles, mumps, and rubella shots, and stating that the hepatitis B vaccine should not be administered until age 12, despite longstanding medical guidance recommending it within 24 hours of birth.&nbsp;Tylenol is Kenvue's largest brand, accounting for a mid-to-high single-digit percentage of total sales, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-autism-report-announcement-eb7c90c8?mod=hp_lead_pos1">noted</a>, citing Morningstar. Trump’s warning also comes as Kenvue continues to face litigation over acetaminophen, with hundreds of lawsuits alleging a link to autism or ADHD currently under appeal after a federal judge last year ruled the scientific evidence unreliable.Meanwhile, acetaminophen remains an important option for pregnant women, and vaccines have saved millions of lives, with UNICEF estimating at least 154 million lives preserved over the last 50 years.The Trump administration also announced steps to position leucovorin, a form of folic acid currently used in chemotherapy support, as a treatment for autism-related symptoms.&nbsp;The FDA approved a version of the drug from GSK and cited a review of 40 patients with cerebral folate deficiency, a rare metabolic disorder linked to neurological symptoms. Medicaid coverage for leucovorin will be extended to autism patients, with expectations that private insurers will follow.Researchers reiterated that there is no solid evidence that acetaminophen causes autism. A 2024 study using 2.5 million Swedish children found no causal relationship. In 2025, a review of 46 previous studies was done, which found an association, but it does not show cause and effect.&nbsp;Researchers advised that pregnant women who need acetaminophen should continue taking it at the lowest dose and for the shortest time. Bigger, randomized trials are still needed to determine leucovorin's potential.On Stocktwits, retail sentiment for Kenvue was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said the administration’s comments unfairly singled out Kenvue as if Tylenol were the only acetaminophen brand on the market, adding that people weren’t about to stop using the drug for everyday needs and calling the concerns overblown.<stembedurl>https://stocktwits.com/FatherofTrades/message/629593979</stembedurl>Another user said that they were buying every dip in Kenvue shares and planned to hold through the lawsuits and any eventual settlement.<stembedurl>https://stocktwits.com/StockCapture/message/629592908</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 18.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish

Investors weighed political scrutiny and unproven health claims as Tylenol’s maker faced renewed controversy, sparking volatility in Kenvue’s stock.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

JNJ
Johnson & Johnson

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JNJ News

JNJ Johnson & Johnson